In two seven-year studies with gold compounds in dogs of both sexes, thrombocytopenia was observed after 45 to 72 months of dosing in three of 14 and two of 14 dogs in high-dose groups that received 2.4 to 3.6 mg/kg of auranofin per day orally or 0.5 to 2.0 mg/kg of gold sodium thiomalate intramuscularly once every three days, respectively. An immune basis for the disorder was suggested by the apparent consumptive nature of the thrombocytopenia (increased bone marrow megakaryocytes and large peripheral blood platelets), the response to corticosteroid therapy and the demonstration of increased platelet-associated immunoglobulin. The latter was demonstrated with a solid phase radioimmunoassay and by electron microscopy using a staphylococcal protein A-colloidal gold conjugate. Platelet-associated immunoglobulin decreased as the platelet counts rose, and in one dog monitored over periods of steroid-induced remissions and subsequent relapses, the amount of platelet-associated immunoglobulin G correlated inversely with the platelet count (r = 0.82). These findings suggest that the long-term administration of gold compounds in dogs is associated with a dose-dependent incidence of thrombocytopenia, which is immune-mediated and similar to that associated with parenteral chrysotherapy in man. The application of tests for platelet-associated immunoglobulin to canine patients with immune thrombocytopenia should be useful in the diagnosis of the disorder in clinical practice.
let antibodies have not been available. This remains a diagnostic problem in veterinary medicine, despite the significant incidence of drug-induced and idiopathic thrombocytopenia in domestic animals which is thought to be immune-mediated.', '7-19326,31. 32 Reasons for the lack of progress in this area have included the unavailability of specific antisera required to perform some of the assays, the difficulty in inducing the disease experimentally. and logistical problems in monitoring animal patients over the course of the spontaneous disease.
The opportunity arose to study the hematologic effects of long-term chrysotherapy during two seven-year studies of gold compounds conducted in a controlled environment, in groups of closely monitored normal dogs free of intercurrent disease. We report here thrombocytopenia without bone marrow depression in five dogs which received high doses of gold and the application of two assays which we have adapted to the dog to demonstrate platelet-associated immunoglobulin in these animals.
Materials and Methods
Two seven-year studies were initiated using purebred beagle dogs (White Eagle Laboratories, Doylestown, PA) eight to nine months of age, which received auranofin (2,3,4,6tetra-0-acet yl-1 -thio-B-D-glucopyranosato-S
[ triethylphosphine] gold6), a new oral organic gold compound, and gold sodium thiomalate (Myochrysine, Merck Sharp & Dohme, West Point, PA), a parenterally administered salt that has been marketed for use in man as an antiarthritic agent for over fifty years. In the first study, 56 dogs were divided into one control and three dosed groups, each consisting of seven males and seven females. Low-, middle-and high-dose groups received oral doses of auranofin which were adjusted over the first month of the study to 0.6 to 0.9, 1.2 to 1.8, and 2.4 to 3.6 mg/kg body weight, respectively, per day. Control dogs were administered the vehicle (0.5% tragacanth gel) per 0s. In a second study, 42 dogs were divided into one control and two dosed groups of the same number and sex distribution as those of the first study. Low-and high-dose groups received intramuscular injections of 0.5 and 2 mg of gold sodium thiomalate/kg body weight, respectively, once every three days. Control dogs were similarly administered an equivalent volume of sterile water. In both studies, routine hematologic and blood chemistry monitoring, which included complete blood cell and platelet counts, was done every six months. Dogs with hematologic changes were monitored at more frequent intervals. Drug administration was either withdrawn from these dogs or, alternatively, the dose was adjusted so as to insure their long-term survival.
Blood samples were collected by jugular vein puncture into tubes that contained ethylenediaminetetraacetic acid, unless otherwise indicated. All blood cell counts, including the determination of platelet size distribution, were done using a Coulter S plus (Coulter Electronics, Inc., Hialeah, FL) or an ELT-800 (Ortho Diagnostics, Raritan, NJ) blood analyzer. Bone marrow aspirates and biopsies were collected from the iliac crest using a Jamshidi biopsy needle (American Pharmaseal, Glendale, CA). Cytologic preparations of aspirates were stained with Wright's stain. Sections of parafin-embedded biopsies were stained with hematoxylin and eosin.
Platelet-associated immunoglobulin was determined using two assays. A modified solid phase radioimmunoassay procedure using 1251-staphylococcal protein A was used to determine platelet-associated immunoglobulin G.I6 Platelets for this assay were prepared from blood collected into 0.13 M (3.8%) sodium citrate in a plastic syringe at a ratio of 9.1, whole blood to anticoagulant. The blood was centrifuged for three minutes at 500 g and the platelet-rich plasma was removed. This procedure was repeated and any additional platelet-rich plasma was added to the first, and centrifuged at 1200 g for 15 minutes. The platelets were then washed once in 1 % ammonium oxalate and three times in 2 mM ethylenediaminetetraacetic acid, 10 mM benzamidine and 100 pg/ml soybean trypsin inhibitor and adjusted to 2.5 X 10' platelets/ ml in Hank's buffered salt solution without calcium, magnesium, bicarbonate or phenol red (GIBCO Laboratories, Grand Island, NY). Forty pl ( lo6 to lo7 platelets) of control or test platelets were placed into each of 12 wells of a 96-well plastic microtiter plate (u-shaped flexible microtiter plates, Falcon MicroTest 1 I I Flexible Assay Plate, Becton Dickinson and Co., Oxnard, CA) and were allowed to incubate in the wells for one hour at room temperature. The wells were then rinsed with 1 % bovine serum albumin in phophate-buffered saline, 0.01 M, pH 7.4. The plate was inverted for five minutes to drain. This wash procedure was repeated twice. Forty ~1 of a dilution of rabbit anti-dog immunoglobulin G in I % bovine serum albumin-phosphate-buffered saline (Miles Laboratories, Inc. Elkhart, IN) was then added to each well. A 1 3 0 dilution was added to the first six wells and a 1: I60 dilution to the remaining six wells. The plates were incubated for one hour at room temperature. The wells were then rinsed three times with 1 % bovine serum albumin-phosphate-buffered saline, as above. Forty pl of 1251-staphylococcal protein A (New England Nuclear, Boston, MA, 2 to 10 mCi/mg) was diluted in 1 % bovine serum albumin-phosphate-buffered saline, added to each well (50,000 to 150,000 counts per minute [cpm]/well), and allowed to incubate for one hour at room temperature. The wells were again rinsed three times. Each well was then cut from its plastic plate, using scissors, and placed in 15 x 85-mm disposable borosilicate glass culture tubes for assay of radioactivity in a Beckman System 5500 Gamma Counter (Beckman Instruments, Inc., Irvine, CA). Background counts ranged from 50 to 250 cpm.
Results were expressed as the ratio of the mean cpm obtained with test platelets using the 1:80 dilution of rabbit anti-dog immunoglobulin G (the dilution which consistently yielded the highest cpm of the two tested) divided by that of the comparable titer employed for control platelets. Platelets from four to six control dogs were generally examined in parallel with test samples, unless otherwise indicated (table I) .
Platelet-associated immunoglobulin was also demonstrated by electron microscopy measured over the course of the disease in two of the dogs (548,553) from the auranofin study using a technique that employed a protein A-colloidal gold conjugate. Citrated-anticoagulated whole blood was collected as above and centrifuged for 30 minutes at 900 g. The buffy coat that contained the platelet fraction was removed and washed three times in phosphate-buffered saline. These cells, or alternatively unwashed buffy coat cells, were then incubated with a 1: 10 dilution of protein A-colloidal gold conjugate (1 5-nm particle size, Polysciences, Wamngton, PA) in phosphate-buffered saline for 15 minutes at 37°C. After incubation, the buffy coat cells were washed three times in 0. I M phosphate buffer (pH 7.4). The cells were suspended in I % glutaraldehyde in 0.1 M phosphate buffer and stored at 4°C for up to four days. The sample was then dehydrated by sequential five-minute incubations in 30, 50, 70, and 95% ethyl alcohol followed by two ten-minute incubations in 100% ethyl alcohol before infiltration and embedding in Spurr's low viscosity epoxy resin. Post fixation with osmium tetroxide was omitted. Buffy coat platelets from test as well as control dogs were examined ultrastructurally using a Zeiss 109 Electron Microscope (Thornwood, N Y ) for electron dense particles on the membrane surface.
The response of the thrombocytopenia to glucocorticoids in vivo was examined in one affected dog from each study (548, 79 1) by administering prednisolone (Tech America Group, Inc., Elkwood, KS) per os at a starting dose of approximately 0.5 mg/kg divided into two equal doses daily, and tapering the dose in accordance with the rise in platelet count or when complete hematologic remission was achieved. 
1948.
Platelet-associated immunoglobulin was monitored over the course of the treatment period of dog 548.
Results
Thrombocytopenia was observed in three of 14 high dose dogs (one male, 553; and two females, 548 and 549) which received auranofin and two of 14 high-dose dogs (two males, 789 and 791) which received gold sodium thiomalate after 45 to 72 months of dosing. Platelet counts during the cytopenic episodes reached nadirs of 4000 to 124,OOO/pl in the five affected dogs. None of the affected dogs had clinical signs of bleeding during these episodes. Coinciding with the thrombocytopenia was the appearance of large platelets in the peripheral blood. Evidence for this change included the observation of macroplatelets on peripheral blood smears ( fig. 1 ) and a shift in platelet volume distribution curves over time toward platelets of larger volume. Bone marrow aspirates and biopsies collected from all five affected dogs during the thrombocytopenic episodes revealed increased numbers of megakaryocytes which appeared morphologically normal and in all stages of maturation (fig. 2) .
The thrombocytopenia was accompanied by a moderate to severe hemolytic anemia with spherocytosis, increased red cell fragility and a marked erythroblastosis (up to 1 18 nucleated red cells/ 100 white blood cells) in dogs 553 and 791. The latter animal was positive on the direct antiglobulin test, using anti-dog immunoglobulin G Coombs sera, with the agglutinin most active at 25°C. Thrombocytopenia was detected in dog 549 while investigating a chronic progressive proteinuria without azotemia. The nephropathy was characterized as renal amyloidosis following examination of a renal biopsy section. Assays for platelet-associated immunoglobulin were not done on this dog.
Cessation of dosing with gold resulted in complete remission of the thrombocytopenia in two dogs (553 and 789) within one week and a rapid but temporary remission in a third (548, fig. 3) . Dogs 791 and 548 achieved complete remission following corticosteroid therapy as described below. Dosing of dog 549 was stopped following the diagnosis of renal amyloidosis, and hematologic remission was established 12 days after this event.
The response to corticosteroid treatment was exam- ined in dogs 548 and 79 1. The oral administration of Platelet-associated immunoglobulin was also obprednisolone resulted in a sharp rise in blood platelets served in dogs 548 and 553 using the protein A-colloidal within five days, rebounding to 4 18,OOO/pl and gold conjugate to examine membrane-bound immu-590,00O/pI in dogs 548 ( fig. 3 ) and 79 1, respectively. noglobulin in unwashed buffy coat cells ( fig. 5) . Washed Dog 79 1 remained in remission after the corticosteroid buffy coat platelets, however, were consistently negative dose was tapered and treatment was withdrawn. Re-for platelet-associated immunoglobulin using this techlapses were observed on several occasions when attempts were made to reduce the dose of prednisolone for dog 548 (fig. 3) , before the drug could finally be withdrawn after 34 weeks of treatment.
Four of the five affected dogs were tested for plateletassociated immunoglobulin G. Levels of platelet-associated immunoglobulin G were increased, relative to controls, in all four dogs during periods of thrombocytopenia (table I, figs. 3, 4). These levels decreased as the platelet counts returned to normal. The amount of platelet-associated immunoglobulin G, measured in dog 548 over periods of steroid-induced remission and subsequent relapses correlated inversely with the plate-nique.
Discussion
In this study we have taken advantage of the controlled conditions of two long-term drug toxicity trials to investigate gold-associated thrombocytopenia in dogs otherwise free of spontaneous disease and other complicating therapy. The cases of thrombocytopenia provided a unique opportunity to study affected dogs over extended periods of time, make observations on the clinical and laboratory course of the iatrogenic disease and correlate these data with variables, such as plateletlet count ( fig. 4 ). associated immunoglobulin, in a way that has hereto- fore been impractical or impossible to do in a human or veterinary clinical setting.
The incidence of thrombocytopenia associated with chrysotherapy in man ranges from 0 to 3%.9*11*'4, 25 Th e fact that we observed an incidence as high as 21% in one dose group probably reflects the high doses administered to these dogs (3.6 mg/kg body weight/day of auranofin compared to the total daily dose of 2 to 6 mg commonly administered to human patients6). This observation, along with the fact that thrombocytopenia was observed exclusively in the high dose group in both studies, suggests that the incidence of this drug effect is dose-dependent .
The thrombocytopenia observed in these dogs was characterized as consumptive and immune-mediated. The consumptive, regenerative nature of the cytopenia was suggested by three observations: the appearance of large granular platelets (macroplatelets) on Wright'sstained peripheral blood smears; a shift in platelet volume distribution toward platelets of larger volume; and the increased number of megakaryocytes in bone marrow aspirates collected during periods of thrombocytopenia. In human patients with shortened platelet sur-vival, platelet volume appears to parallel stimulation of thrombopoiesis. 22 This phenomenon was documented in our dogs both by the morphologic assessment of blood platelets and standard aperture impedance techniques for determining the distribution of platelet volume. Finally, bone marrow megakaryocytes were increased in number in all five dogs during thrombocytopenic episodes, an observation that strongly suggests accelerated platelet c o n s~m p t i o n .~~ An immune-mediated mechanism for the thrombocytopenia was suggested by the response to corticosteroid therapy, and the demonstration of increased platelet-associated immunoglobulin. Although corticosteroid treatment of drug-induced immune thrombocytopenia in man remains controversial, it appears to be effective in patients receiving ~h r y s o t h e r a p y .~~~~ ' Corticosteroids are thought to raise the platelet count by reducing the removal of antibody-coated platelets by the mononuclear phagocyte system. 13 Although there are presently no generally accepted criteria used to diagnose drug-induced immune thrombocytopenia, l 2 many investigators rely on the demonstration of either antiplatelet antibody in serum or increased levels of platelet-associated immunoglobulin G. l o A similar criterion has been suggested in veterinary medicine."
Sensitive direct assays for platelet-associated immunoglobulin have only recently become available to physicians, and their application to veterinary patients has not been previously reported. In these studies, plateletassociated immunoglobulin was determined using two assays employing protein A. Protein A has been shown to bind to dog immunoglobulin G and immunoglobulin M30 and is therefore an appropriate ligand to use in direct assays that measure platelet-associated immunoglobulin in this species.
As with red cells, elution of antibody from platelets during separation and handling remains a potential source of artifact in all assays designed to measure membrane-bound immunoglobulin. The observation that washed platelets were negative for colloidal goldconjugated protein A during periods of thrombocytopenia, when positive results could be demonstrated in their unwashed counterparts as well as the protein A solid phase radioimmunoassay, suggests that the binding affinity of the putative immunoglobulin for the platelet membrane may be variable, with elution occurring during the washing procedure. Consequently, the potential for false negatives, or alternatively detecting non-specifically bound plasma immunoglobulin in unwashed specimens may be greater using this assay. This observation suggests that further work is necessary before this technique for assessing platelet-associated immunoglobulin can be widely applied with confidence. Nevertheless, the results of these tests correlate well with each other and, more importantly, with the progress of the disease, suggesting that both assays may be useful in diagnosing and monitoring similar spontaneous immunopathy in dogs.
Human patients with drug-induced immune thrombocytopenia, in general, recover within days following discontinuation of the drug. Gold-induced thrombocytopenia. however, is a major exception; the disorder can persist for weeks, months or even years after discontinuation of chrysotherapy.'2 Consistent with these observations in man is the course of dog 548 in this study, which, despite discontinuation of dosing, continued to show thrombocytolytic disease as long as four months thereafter. It has been widely speculated that this phenomenon in man reflects tissue-bound gold that is being slowly released or, alternatively, the induction by the drug of a true autoimmune disorder.12 The latter possibility is particularly interesting in light of the increased platelet-associated immunoglobulin G that was demonstrated directly in these affected dogs, without prior incubation of platelets with drug and autologous serum. In thrombocytopenia associated with other drugs in man, the incubation of platelets with drug and the patients serum has been necessary in order to show increased platelet-bound antibody using the solid-phase radioimmunoassay employed in this study. l o Thus, long-term chrysotherapy in the dog, as in man, can be associated with immune-mediated thrombocytopenia. This is the first report in which the drug effect is characterized and followed over time, under carefully controlled conditions, in subjects free of complicating spontaneous immunopathy and other drug therapy. As in man, the iatrogenic immune cytopenia resembles the spontaneous idiopathic autoimmune disorder, therefore presenting, at times, a more difficult management problem than other drug-induced immune thrombocytopenias. The application of tests for platelet-associated immunoglobulin to canine patients with immune thrombocytopenia should be useful in the diagnosis of the disorder in clinical practice.
